ArticleJournal of thoracic disease2025
Nomogram for predicting the prognosis of metastatic thymic epithelial tumors.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The majority of patients diagnosed with thymic epithelial tumors (TETs) are often at an advanced stage that precludes cure. This study aimed to develop a nomogram to predict the prognosis of metastatic TETs. Methods: Patients diagnosed as metastatic TETs in Sun Yat-sen University Cancer Center from July 2000 to November 2021 were retrospectively reviewed. A nomogram was developed to predict the prognosis of metastatic TETs. The performance of the nomogram was assessed by the concordance index (C-index), calibration curves, and decision curve analysis curves. Based on the nomogram scores, patients were divided into different prognostic groups. Results: A total of 254 patients were enrolled. The median overall survival (OS) was 53.03 months [95% confidence interval (CI): 40.56-65.51]. Univariate and multivariate analyses showed that World Health Organization (WHO) histologic classification type C, Masaoka-Koga stage IVb, Karnofsky performance status (KPS) score 70-80, and baseline serum albumin level <40 g/L were independent poor prognostic factors of OS. These factors were then taken into the development of nomogram model. The C-index was 0.68 (95% CI: 0.59-0.79), indicating good performance. The risk groups were categorized by nomogram scores with a threshold at 112 score. The median OS in the high-risk group was much shorter than that of the low-risk group [28.60 versus 74.17 months, hazard ratio (HR): 2.44; 95% CI: 1.65-3.62; P<0.001]. Conclusions: WHO histologic classification, Masaoka-Koga stage, KPS score, and baseline serum albumin level were identified as independent prognostic factors of OS in metastatic TETs. This study developed a nomogram model effectively predicting the prognosis of metastatic TETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.